Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
Table 3
Pre-treatment values and fold-changes in plasma biomarkers after treatment with vandetanib and cetuximab (days 8 and 15) and with vandetanib, cetuximab and irinotecan (day 21, cycle 3 and cycle 5) in metastatic colorectal cancer patients.